An Overview of Parkinson s Medication used in Multiple System Atrophy

Similar documents
An Overview of Parkinson s Medication used in Multiple System Atrophy

Parkinson s disease. Information for patients and carers. The Leeds Teaching Hospitals NHS Trust

Appendix 2: Admissions checklists for people with Parkinson s

MANAGEMENT OF PATIENTS WITH PARKINSON S DISEASE WHO ARE NIL BY MOUTH OR WITH A COMPROMISED SWALLOW

Guidelines for acute treatment of patients with Parkinson s disease including those who are nil by mouth

Fatigue in MSA. Introduction. What is fatigue? Recognising fatigue

PARKINSON S MEDICATION

Monitoring Blood Pressure

Monitoring Blood Pressure

Clinical Guideline for the management of inpatients with Parkinson s disease

Acute management of in-patient Parkinson s Disease patients

ACUTE MANAGEMENT OF PARKINSON S PATIENTS WHO ARE NIL BY MOUTH (NBM) OR WHO HAVE A COMPROMISED SWALLOW NHS LANARKSHIRE PARKINSON S TEAM

Also there may be some increased saliva production by the autonomic nervous system.

Management of Parkinson s Disease in Primary and Secondary care for patients with compromised swallow or those patients deemed Nil By Mouth.

Scottish Medicines Consortium

Parkinson's Disease and how you can make a difference with medication

Common medicines given to neurology patients on discharge from hospital

Parkinson s Disease. Gillian Sare

Thinking about advanced parkinson S

Commonly encountered medications and their side effects - what the generalist needs to know

CLINICAL GUIDELINE FOR THE MANAGEMENT OF INPATIENTS WITH PARKINSON S DISEASE

Motor Fluctuations Stephen Grill, MD, PHD Parkinson s and Movement Disorders Center of Maryland and Johns Hopkins University

GUIDELINES FOR THE MANAGEMENT OF PATIENTS WITH PARKINSON S DISEASE (PD) ADMITTED TO HOSPITAL. Reviewer s Name, Title & address:

The symptoms of the Parkinson s disease may vary from person to person. The symptoms might include the following:

parts of the gastrointenstinal tract. At the end of April 2008, it was temporarily withdrawn from the US Market because of problems related to

Best Medical Treatments for Parkinson s disease

CENTENE PHARMACY AND THERAPEUTICS NEW DRUG REVIEW 3Q17 July August

New Medicines Committee Briefing July 2011

Final Appraisal Report. ) for the treatment of idiopathic Parkinson s disease. Ropinirole prolonged-release (Requip XL. GlaxoSmithKline UK

Parkinson s Disease Prescribing Guidelines for use in Primary and Secondary Care

Parkinson s Well-Being Map TM

Summary of Patient < 3y at Visit 11 (90 months)

A Guide to Brain and Tissue Donation for Research

Living with Postural Hypotension

NHS Greater Glasgow And Clyde Pain Management Service. Information for Adult Patients who are Prescribed. Carbamazepine. For the Treatment of Pain

Clinical Policy: Safinamide (Xadago) Reference Number: CP.CPA.308 Effective Date: Last Review Date: Line of Business: Commercial

A guide to Multiple System Atrophy for: General Practitioners

Drug treatments for Alzheimer s disease

Anticholinergics. COMT* Inhibitors. Dopaminergic Agents. Dopamine Agonists. Combination Product

Parkinson s Disease Medications: Professionals Edition

History Parkinson`s disease. Parkinson's disease was first formally described in 1817 by a London physician named James Parkinson

Medicines Management and the Unwell Parkinson s Patient

Medicines in Scotland: What s the right treatment for me? Information for patients and the public

Patient information sheet: BuTrans Patch This information should be read in conjunction with the Taking Opioids for pain information leaflet

Cardinal Features of Parkinson s. Management of Parkinson s Disease. Drug Induced Parkinson s. Other Parkinson s Symptoms.

Why do I need to use Fentanyl Patches?

Optimizing Clinical Communication in Parkinson s Disease:

Objectives. Emerging Treatments in Parkinson s s Disease. Pathology. As Parkinson s progresses it eventually affects large portions of the brain.

The Fresco Institute for Parkinson's and Movement Disorders

ARE YOUR LEVODOPA PILLS WORKING LIKE THEY USED TO?

Opioid Type Pain Killers

ReQuip 0.25 mg, 1 mg, 2 mg, 5 mg film-coated tablets ropinirole (as the hydrochloride)

Medications used to treat Parkinson s disease

NHS Greater Glasgow And Clyde Pain Management Service. Information for Adult Patients who are Prescribed. Pregabalin. For the Treatment of Pain

What s new for diagnosing and treating Parkinson s Disease?

HOW TO MANAGE MY SYMPTOMS & MEDICINES PARKINSON S PASSPORT. On time, every time with Parkinson s medicines. Endorsed by Australian College of Nursing

Amitriptyline, Nortriptyline or Imipramine

NHS Greater Glasgow And Clyde Pain Management Service. Information for Adult Patients who are Prescribed. Duloxetine. For the Treatment of Pain

Your medicines for heart failure

Continence in MSA. How the bladder works

Pharmacologic Treatment of Parkinson s Disease. Nicholas J. Silvestri, M.D. Assistant Professor of Neurology

It is possible to manage the bladder problems of MSA even if they cannot be cured.

Patient guide to Capecitabine chemotherapy with radiotherapy for rectal cancer

A Review on Parkinson s Disease: Its Surgical Inventional Therapies, Pathophysiology and Treatment

If you have dementia, you may have some or all of the following symptoms.

Key Concepts and Issues in Parkinson s Disease in 2016

Weaning off requip. Cari untuk: Cari Cari

Where do you get most of your information about medications?

Treatment of Parkinson s Disease and of Spasticity. Satpal Singh Pharmacology and Toxicology 3223 JSMBS

Program Highlights. Michael Pourfar, MD Co-Director, Center for Neuromodulation New York University Langone Medical Center New York, New York

Managing your pain at home after surgery. Information for patients

Parkinson s Disease Current Treatment Options

A Review on Parkinson s Disease: Its Pathophysiology, Treatment and Surgery

Guideline for the Management of Parkinson s Disease Medication Trust Reference B26/2017

Medicines to treat pain in adults. Information for patients and carers

Pharmacologic Treatment of Parkinson s Disease. Nicholas J. Silvestri, M.D. Associate Professor of Neurology

Dorset Medicines Advisory Group SHARED CARE GUIDELINES FOR PRESCRIBING ENTACAPONE (INCLUDING IN COMBINATION) OR OPICAPONE IN PARKINSON S DISEASE

Re-Submission. Scottish Medicines Consortium. rasagiline 1mg tablet (Azilect ) (No. 255/06) Lundbeck Ltd / Teva Pharmaceuticals Ltd.

Slow Release Opioids. Morphine (Zomorph/MST) Oxycodone (Longtec, Oxycontin) Tapentadol (Palexia) For the Treatment of Pain

Communicating About OFF Episodes With Your Doctor

Sofosbuvir, Pegylated Interferon and Ribavirin for the Treatment of Hepatitis C

Understanding Parkinson s Disease Important information for you and your loved ones

Section 1: What is Parkinson s? Parkinson's Disease Webinar 4/27/2012. April 27th, :00-1:00 PM EST

Drugs for Parkinson s Disease

CENTRE FOR PHARMACY POSTGRADUATE EDUCATION. Parkinson s disease. Book2. A CPPE focal point programme

Pharmacy Coverage Guidelines are subject to change as new information becomes available.

Drug Therapy of Parkinsonism. Assistant Prof. Dr. Najlaa Saadi PhD Pharmacology Faculty of Pharmacy University of Philadelphia

REFERENCE CODE GDHC235CFR PUBLICAT ION DATE M ARCH 2014 PARKINSON S DISEASE - US DRUG FORECAST AND MARKET ANALYSIS TO 2022

Parkinson s Disease WHERE HAVE WE BEEN, WHERE ARE WE HEADING? CHARLECE HUGHES D.O.

MEDICATION GUIDE DUOPA (Do-oh-pa) (carbidopa and levodopa) enteral suspension

DESCRIPTION.

[SIMIPEX XR] modified release tablets

Oral N-Acetyl CystieneTablets. Patient Information

Disclosures. Objectives. What s Shaking? Tremors and Movement Disorders

Controlling nausea and vomiting: anti-emetic therapy advice

Pain Management after Discharge from Hospital

PACKAGE LEAFLET. Page 1 of 6

Management of Neurological Conditions at End of Life

Patient Action Plan Patient Action Plan

Package Leaflet: Information for the user Kemadrin 5 mg Tablets Procyclidine hydrochloride

Transcription:

Introduction The cause of Parkinson s symptoms The types of Parkinson s drugs used in MSA Finding the best medication Additional medication Drugs to avoid Further information An Overview of Parkinson s Medication used in Multiple System Atrophy Introduction This leaflet is for people with MSA, their carers and their family members. It provides information about the drugs most commonly used to help manage the condition and is aimed at increasing your understanding of the available drugs rather than prescribing what may be of benefit. Whilst there is no specific treatment for MSA, some of the symptoms may be managed by Parkinson s medications. They are not effective for everyone with MSA, but may be beneficial for some, particularly those who have Parkinson-type symptoms. We cannot advise on ideal combinations or provide details about the strengths or duration of action for each medication. Each person with MSA will respond differently to medication and you should discuss these issues with your Neurologist, Specialist or Parkinson s Nurse Specialist (PNS). The cause of Parkinson s symptoms The cause of Parkinson s is still unknown but it occurs due to a loss of nerve cells in the brain. The lost nerve cells are responsible for producing a chemical in the body called dopamine. Dopamine is a chemical that transmits messages to parts of the brain involved with the coordination of movement. The loss of the dopamine producing cells causes a lowering of dopamine in the body which causes a loss of control over bodily movement. A common treatment of the symptoms of Parkinson s is to increase the dopamine levels. The increased levels of dopamine allow greater control over bodily movement. Common Parkinson s medication attempt to increase the dopamine levels in different ways and it is these different ways that form the basic medication groups.

Types of Parkinson s drugs used in MSA Levodopa Levodopa is one of the main drugs used in the treatment of Parkinson s symptoms. Levodopa is a chemical building block that the body converts into dopamine, increasing the levels of dopamine in the brain. Levodopa can come in branded and unbranded forms. Other names for Levodopa include: Co-beneldopa (Madopar or Madopar CR) Co-careldopa, (Caramet CR, Sinemet, Sinemet Plus, Sinemet CR, Half Sinemet CR, Lecado) Co-careldopa plus entacapone (Stalevo) Levodopa can cause nausea and vomiting: Domperidone (Motilium) is the most common antisickness drug prescribed to prevent this. It is the only anti-sickness medication someone with MSA may take, others will make symptoms of MSA worse. Dopamine Agonists An agonist is a chemical that binds to a receptor and activates it to produce a biological response. Dopamine agonists are drugs that work by heightening the activity of dopamine receptors in the brain. This makes is easier for the brain to receive dopamine signals. In management of Parkinson s it s sometimes given in conjunction with Levodopa, the Levodopa increases the amount of dopamine and the agonist increases the ability to receive that dopamine. Dopamine agonists come in branded and unbranded forms. Common names for dopamine agonists include: Pramipexole (Mirapexin, Mirapexin prolonged release) Ropinirole (Adartrel, Ralnea XL, Requip, Requip XL, Rotigotine (Neupro) Neupro/Rotigotine Transdermal Patch A dopamine receptor agonist this may be used when swallowing is difficult or for the treatment of Restless Leg Syndrome. It is delivered via a patch that is placed on the skin every 72 hours. Monoamine Oxidase Type B (Mao-B) Inhibitors MAO-B is an enzyme that the body releases to break down any left over dopamine. This left over dopamine is there because the dopamine receptors only need so much in order to receive the brain signal. The excess dopamine is then destroyed and MAO-B inhibitors work by breaking down the MAO-B before it is able to destroy the dopamine, which increases the chance for a signal to be received. Again, in Parkinson s treatment it is common for them to be used in conjunction with other drug types. MAO-B Inhibitors come in generic and brand forms. They are commonly called: Rasagiline (Azilect) Selegiline (Eldepryl, Zelapar)

Glutamate Antagonist An antagonist blocks the action of a agonist. It isn t entirely clear how glutamate antagonists work but possibly they inhibit the action of glutamate receptors which increases dopamine release and blocks the re-uptake of dopamine. This will increase the likelihood of dopamine messages being transmitted through the brain. It is not prescribed very often in Parkinson s treatment and has only a mild impact on main symptoms, but can have a positive effect on tiredness and stiffness. The only glutamate antagonist drug used in Parkinson s treatment is called: Amantadine (Symmetrel) Finding the best medication MSA affects everyone differently. Because of this there is no correct dose or medication. Finding the best medication, dose and timing may take some time and will need some changes along the way. Because the symptoms of MSA can change over time, your medication will sometimes have to change, too. While you may be able to talk to your GP about any side effects of medication you experience, or speak to them about issues that aren t related to the condition, ideally, you should discuss Parkinson s medication with your Neurologist, Specialist, Parkinson s Nurse Specialist (PNS) or Pharmacist. It is important not to make any changes to your own medication without talking to your specialist or PNS first. You will be advised about timing of medication by your prescriber (one of the people mentioned above). It is beneficial to take any Parkinson s medication as close to the times given as possible. If you should develop any side effects from medication do discuss this with your specialist or PNS before stopping the medication. It can be dangerous to stop taking Parkinson s medication suddenly. Generally these medications should be reduced gradually with the advice and guidance of your PNS. Additional medication If you have other medical conditions, this may affect your Parkinson s symptoms and also how effective the Parkinson s drugs can be. Some medications for other conditions can make Parkinson s symptoms worse (see below). If you have a problem with your digestive system, such as constipation (which is a common symptom in MSA) this may affect how well your drugs enter your bloodstream and may reduce the effectiveness of the medication. Parkinson s drugs can interact with drugs used for other conditions. Herbal or complementary treatments may also impact on Parkinson s drugs. If you want to take a non-prescription medicine, check with your pharmacist first that it is safe. Anti-sickness, travel remedies, decongestants or cold remedies can affect some Parkinson s medications. If you need to use these, check with your pharmacist which one is safest to use.

Your Specialist, Parkinson s Nurse Specialist or pharmacist can give you advice on specific interactions with different medications. Drugs to avoid Some drugs can bring on Parkinson s-like symptoms or react badly with Parkinson s drugs and should be avoided unless they re recommended by a specialist. These are some (but not all) of the drugs to avoid in MSA: Metoclopramide (Maxalon) Prochlorperazine (Stemetil) Chlorpromazine (Largactil) Fluphenazine (Modecate) Fluphenazine with nortriptyline (Motival) Perphenazine (Fentazin/Triptafen) Trifluoperazine (Stelazine) Flupenthixol (Fluanxol/Depixol) Haloperidol (Serenace/Haldol) If you have any queries about medication, contact your Specialist, Parkinson s Nurse Specialist or pharmacist. Further information Parkinson s UK Website contains detailed information about Parkinson s drugs. W: www.parkinsons.org.uk/about-parkinsons/treating-parkinsons.aspx The electronic Medicines Compendium (emc) Contains accessible information about medicines licensed in the UK and patient medicines guides. W: www.medicines.org.uk NHS Choices Medicines Information about medications and side effects and contains an online search facility for finding your local pharmacist. W: www.nhs.uk/medicine-guides/pages/default.aspx

Samantha Pavey: T: 0203 371 0003 E: samantha.pavey@msatrust.org.uk Katie Rigg T: 01434 381 932 E: katie.rigg@msatrust.org.uk Jill Lyons T: 01934 316 119 E: jill.lyons@msatrust.org.uk Emma Saunders T: 0330 221 1030 E: emma.saunders@msatrust.org.uk REVISION DATE: 05/17 REVIEW DATE: 05/19 VERSION: 1.3 Disclaimer We have taken every care to ensure the accuracy of the information contained in this publication. It is produced independently, is not influenced by sponsors and is free from endorsement. The information should not be used as a substitute for the advice of appropriately qualified professionals, if in any doubt please seek advice from your doctor or legal professional. References for this information sheet are available by contacting support@msatrust.org.uk Feedback Your feedback helps us ensure we are delivering information to the highest standard. If you have any comments or suggestions please complete a short survey by following the links from our website: www.msatrust.org.uk or by contacting us at support@msatrust.org.uk